Is flu vaccine for 2026-7 RNA based!

The 2026–2027 flu vaccine formulations have not been announced, so no one can tell you whether they will include an mRNA platform.

The evidence retrieved for this question is empty. That is itself informative. The seasonal flu vaccine composition for a given year is typically set in February or March of that year by the WHO and FDA advisory committees. As of now, no public decision or manufacturer announcement exists for the 2026–2027 season. The question asks about a product that has not yet been specified.

What we do know from the general record is that mRNA flu vaccines are in development by Moderna, Pfizer, and others, and some have entered late-stage trials. But a trial candidate is not a marketed product. The 2024–2025 and 2025–2026 seasonal flu vaccines in the US are all egg-based, cell-based, or recombinant protein—none are mRNA. Whether an mRNA flu shot appears in 2026–2027 depends on FDA licensure decisions, manufacturing capacity, and uptake, none of which are settled.

My call: the evidence does not answer this question because the product does not yet exist. Confidence: not clear—this is a question about a future regulatory event, not a scientific one.